Updates provide comprehensive insights for tracking patient progression and analyzing clinical data, company says.
Climedo, an eCOA and electronic data captire (EDC) software company, has released a number of enhancements to its progression and benchmark features for clinical studies. According to the company, these updates mark a significant milestone in empowering healthcare professionals (HCPs) and researchers with more comprehensive insights for tracking patient progression and analyzing clinical data.
The upgraded progression and benchmarking features include progression comparison, benchmarking refinement, robust data filtering, rich text functionality, and a dashboard selection overhaul.
Reference: Climedo Releases Improved Features to Revolutionize Clinical Data Insights and Progress Tracking. Climedo. September 19, 2023. Accessed September 19, 2023. https://climedo.de/en/press/climedo-releases-improved-features-to-revolutionize-clinical-data-insights-and-progress-tracking/
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Novel Agent Shows Superiority Over Placebo in Reducing Monthly Migraine Days
September 5th 2024Lu AG09222 shows promise as first-in-class medication that prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine attacks.